Results 211 to 220 of about 15,210 (229)

Management of myelodysplastic syndromes after failure of response to hypomethylating agents

Therapeutic Advances in Hematology, 2019
Guillermo Montalban-Bravo
exaly  

Hypomethylating Agents

2008
openaire   +1 more source

A safe and effective DNA hypomethylating agent

Nature Reviews Drug Discovery, 2021
openaire   +1 more source

Venetoclax combined with hypomethylating agents and the CAG regimen in relapsed/refractory AML: a single-center clinical trial

Frontiers in Immunology, 2023
exaly  

Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents

EBioMedicine, 2018
Matthieu Duchmann, Fevzi F Yalniz, David A Sallman   +2 more
exaly  

Epigenetics in focus: Pathogenesis of myelodysplastic syndromes and the role of hypomethylating agents

Critical Reviews in Oncology/Hematology, 2013
Valeria Santini, Ari M Melnick, Estelle Duprez   +2 more
exaly  

Treatment patterns and outcomes in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis

Leukemia and Lymphoma, 2021
exaly  

Hypomethylating agents (HMA) treatment for myelodysplastic syndromes: alternatives in the frontline and relapse settings

Expert Opinion on Pharmacotherapy, 2017
Thomas Prebet, Steven D Gore
exaly  

LILRB4 expression in chronic myelomonocytic leukemia and myelodysplastic syndrome based on response to hypomethylating agents

Leukemia and Lymphoma, 2020
Kelly S Chien, Caleb A Class, Guillermo Montalban-Bravo   +2 more
exaly  

DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia

Seminars in Cancer Biology, 2018
Christian Flotho, Sebastian Sommer, Michael Lübbert   +2 more
exaly